2026 Lewis Group: Spatial biology to understand and rejuvenate failing hearts — Radcliffe Department of Medicine

2026 Lewis Group (MRC Enterprise iCase): High throughput human systems for target discovery and validation in tissue fibrosis — Radcliffe Department of Medicine

Our research group at Oxford develops and applies advanced imaging techniques across various spatial scales, from subcellular to whole-heart, to better understand cardiovascular disease mechanisms, identify new therapeutic targets, and enhance early detection of treatment effects in experimental medicine trials. By integrating human cells, tissue samples, and non-invasive imaging of research and trial participants and patients, we aim to maximise the translational potential and mechanistic insights of our work. Current projects focus on metabolic and immunological pathways in heart failure, exploiting state-of-the-art spatial profiling techniques. We collaborate with a broad network of local, national, and international partners across academia and industry, and we welcome applicants with interdisciplinary expertise – please reach out to discuss current opportunities.

Andrew undertook doctoral research in translational cardiovascular imaging in the group of Professor Stefan Neubauer in Oxford. He was then appointed as a Clinical Lecturer in Oxford, prior to a post-doctoral fellowship at Massachusetts General Hospital and Harvard Medical School in the laboratory of Professor Matthias Nahrendorf. Following award of a BHF Intermediate Clinical Fellowship, he was appointed as a Principal Investigator and Group Leader at the Radcliffe Department of Medicine and the Oxford BHF Centre for Research Excellence as well as Honorary Consultant Cardiologist at the Oxford Heart Centre. Andrew is a Fellow of the Royal College of Physicians of London, and the Kemp Postdoctoral Fellow at Lincoln College Oxford.